Abstract
Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Current Drug Discovery Technologies
Title: Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity
Volume: 4 Issue: 1
Author(s): Jeffrey Wang and Ying Huang
Affiliation:
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Abstract: Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Export Options
About this article
Cite this article as:
Jeffrey Wang and Ying Huang , Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115485
DOI https://dx.doi.org/10.2174/157016307781115485 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Amphiphilic Cyclodextrin Derivatives for Targeted Drug Delivery to Tumors
Current Topics in Medicinal Chemistry Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Goniothalamin-Related Styryl Lactones: Isolation, Synthesis, Biological Activity and Mode of Action
Current Medicinal Chemistry Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Commentary (Research Highlights Utilizing Neuro-Inflammation: Turning Degeneration to Regeneration)
CNS & Neurological Disorders - Drug Targets Hemopoietic Cells with Features of the Mast Cell and Basophil Lineages and their Potential Role in Allergy
Current Drug Targets - Inflammation & Allergy Phanginin R Induces Cytoprotective Autophagy via JNK/c-Jun Signaling Pathway in Non-Small Cell Lung Cancer A549 Cells
Anti-Cancer Agents in Medicinal Chemistry Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells
Current Genomics Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pathway (UPP) Proteins
Current Protein & Peptide Science Saccharomyces Cerevisiae as a Genetic Model in Anticancer Therapy
Current Pharmacogenomics Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design FANCJ Helicase Operates in the Fanconi Anemia DNA Repair Pathway and the Response to Replicational Stress
Current Molecular Medicine Review of Bioinformatics and Theoretical Studies of Acetylcholinesterase Inhibitors
Current Bioinformatics Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations
Current Cancer Drug Targets Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs
Medicinal Chemistry Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science The Detection of Pb<sup>2+</sup> Using Glutathione Capped Mn Doped ZnS QDs
Current Analytical Chemistry Nutritional Antioxidants Mechanisms of Action, Analyses of Activities and Medical Applications
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry